LT3253401T - Akromegalijos gydymas geriamuoju oktreotidu - Google Patents

Akromegalijos gydymas geriamuoju oktreotidu

Info

Publication number
LT3253401T
LT3253401T LTEPPCT/US2016/016384T LTUS2016016384T LT3253401T LT 3253401 T LT3253401 T LT 3253401T LT US2016016384 T LTUS2016016384 T LT US2016016384T LT 3253401 T LT3253401 T LT 3253401T
Authority
LT
Lithuania
Prior art keywords
oral octreotide
treating acromegaly
acromegaly
treating
octreotide
Prior art date
Application number
LTEPPCT/US2016/016384T
Other languages
English (en)
Inventor
Roni Mamluk
Original Assignee
Amryt Endo, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56552726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3253401(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amryt Endo, Inc. filed Critical Amryt Endo, Inc.
Publication of LT3253401T publication Critical patent/LT3253401T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2016/016384T 2015-02-03 2016-02-03 Akromegalijos gydymas geriamuoju oktreotidu LT3253401T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562111369P 2015-02-03 2015-02-03
US201562136012P 2015-03-20 2015-03-20
PCT/US2016/016384 WO2016126830A1 (en) 2015-02-03 2016-02-03 Method of treating diseases

Publications (1)

Publication Number Publication Date
LT3253401T true LT3253401T (lt) 2025-07-10

Family

ID=56552726

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/016384T LT3253401T (lt) 2015-02-03 2016-02-03 Akromegalijos gydymas geriamuoju oktreotidu

Country Status (20)

Country Link
US (9) US10238709B2 (lt)
EP (2) EP3253401B1 (lt)
AU (3) AU2016215350B2 (lt)
CA (1) CA2975599A1 (lt)
DK (1) DK3253401T3 (lt)
ES (1) ES3029566T3 (lt)
FI (1) FI3253401T3 (lt)
HR (1) HRP20250645T1 (lt)
HU (1) HUE071943T2 (lt)
IL (2) IL253706A0 (lt)
LT (1) LT3253401T (lt)
MA (1) MA41462B1 (lt)
MD (1) MD3253401T2 (lt)
PL (1) PL3253401T3 (lt)
PT (1) PT3253401T (lt)
RS (1) RS66942B1 (lt)
SI (1) SI3253401T1 (lt)
SM (1) SMT202500243T1 (lt)
WO (1) WO2016126830A1 (lt)
ZA (3) ZA201705877B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
AU2015360485B2 (en) * 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
PL3253401T3 (pl) 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
US20220202911A1 (en) * 2020-12-28 2022-06-30 Amryt Endo, Inc. Oral octreotide therapy in combination with digoxin or lisinopril
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3208763A1 (en) * 2021-01-21 2022-07-28 Nbo Pharma Llc Intranasal formulations and delivery of somatostatin mimetics and uses thereof
WO2022182779A1 (en) * 2021-02-24 2022-09-01 Nbo Pharma Llc Methods and therapeutic combinations for treating idiopathic intracranial hypertension and cluster headaches
JP2024520274A (ja) * 2021-05-25 2024-05-24 クリネティックス ファーマシューティカルズ，インク． 疾患の治療のためのソマトスタチンモジュレータの使用

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
SE376722B (lt) 1971-03-30 1975-06-09 S E Friberg
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4489097A (en) 1976-07-28 1984-12-18 The Procter & Gamble Company Intravenous solutions with antimicrobial agent
JPS53107408A (en) 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
GB2051574B (en) 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4544500A (en) 1982-04-14 1985-10-01 Scripps Clinic And Research Foundation Synthetic foot and mouth disease antigen
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4508828A (en) 1983-03-21 1985-04-02 Immuno Nuclear Corporation Bioassay of parathyroid hormone
US4572915A (en) 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4985404A (en) 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4650665A (en) 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4732971A (en) 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
HU198626B (en) * 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
DE3709861A1 (de) 1987-03-25 1988-10-06 Henkel Kgaa Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE3738236A1 (de) 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
ZA898331B (en) 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
NZ233403A (en) 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
ATE113471T1 (de) 1989-08-17 1994-11-15 Cortecs Ltd Arzneiformulierungen.
US5665384A (en) 1990-04-06 1997-09-09 Rhone-Poulenc Rorer S.A. Oily capsules of ketoprofen
GB9013448D0 (en) 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
IT1243435B (it) 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5254331A (en) 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
WO1993008804A1 (fr) 1991-11-08 1993-05-13 Kyoto Pharmaceutical Industries, Ltd. Preparation pharmaceutique contenant un compose de prostaglandine a administrer par voie rectale ou vaginale
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5246716A (en) 1992-01-10 1993-09-21 W. Neudorff Gmbh Kg Fatty acid-based antifungal composition having residual activity
DE4203170A1 (de) 1992-02-05 1993-08-12 Basf Ag Verfahren zur herstellung von e-oximethern von phenylglyoxylsaeureestern
GB9203769D0 (en) 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
IL103224A (en) 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
US5288492A (en) 1992-11-13 1994-02-22 Morris Michael A Decongestant composition containing aloe vera
DK17093D0 (da) 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
IT1263840B (it) 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
CA2209016A1 (en) 1994-12-28 1996-07-04 Teikoku Hormone Mfg. Co., Ltd. Pharmaceutics for mucosal administration
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US6696413B2 (en) 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5686488A (en) 1995-08-25 1997-11-11 Alcon Laboratories, Inc. Polyethoxylated castor oil products as anti-inflammatory agents
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
US5665711A (en) 1995-12-12 1997-09-09 Yoshitomi Pharmaceutical Industries, Ltd. Antitumor composition for oral administration
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6280745B1 (en) 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
EP0889722B1 (en) 1996-03-28 2002-11-20 Takeda Chemical Industries, Ltd. Sustained-release preparation and its production
US6214792B1 (en) 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
US5726154A (en) 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
CA2259418A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
US6193986B1 (en) 1997-02-25 2001-02-27 The Nisshin Oil Mills, Ltd. Oily composition with increased stability and process for producing the same
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
CN1251035A (zh) 1997-03-25 2000-04-19 武田药品工业株式会社 胃肠粘膜粘附性药物组合物
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
IT1296914B1 (it) 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera
IL123143A (en) 1998-02-02 2001-08-26 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
JPH11246439A (ja) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CN1160079C (zh) 1998-03-11 2004-08-04 格勒兰制药株式会社 发泡性肠溶制剂
CA2269050A1 (en) 1998-04-14 1999-10-14 Shigeo Yanai Method for transdermal administration of gp iib/iiia antagonist
ID27131A (id) 1998-06-26 2001-03-01 Pfizer Prod Inc Proses yang lebih baik untuk membuat hasil adisi basa schiff dari amina dengan o-hidroksi aldehida dan komposisi materi yang didasarkan padanya
US6150333A (en) 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6284223B1 (en) 1998-10-15 2001-09-04 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
CA2363123C (en) 1999-02-22 2011-09-06 Kenneth Iain Cumming Solid oral dosage form containing an enhancer
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383527B1 (en) 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
WO2000074736A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6159935A (en) 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
FR2803202B1 (fr) 2000-01-03 2004-04-16 Capsulis Compositions pharmaceutiques destinees a une adminstration par voie orale
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US20020091623A1 (en) 2000-12-04 2002-07-11 Daniels Alan F. System and methods for an electronic real estate trading environment
ES2295397T3 (es) 2001-04-18 2008-04-16 Prometic Biosciences Inc. Acidos grasos como factores de supervivencia y activacion de neutrofilos.
EP1390383B1 (en) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
US6528667B2 (en) 2001-05-14 2003-03-04 Phoenix Research Corporation Phosphated castor oil and derivatives
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
CN101961317A (zh) 2001-07-06 2011-02-02 生命周期药物公司 受控制的凝聚
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
KR100425755B1 (ko) 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
DK1429731T3 (da) 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2463067A1 (en) 2001-10-26 2003-05-08 Sciclone Pharmaceuticals, Inc. Pharmaceutical formulations comprising substituted xanthine compounds
US6710195B2 (en) 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
WO2003057128A2 (en) 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
TWI287986B (en) 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US6890961B2 (en) 2002-02-01 2005-05-10 Micelle Products, Inc. Clear micellized formulations of β-carotene and method of treating leukoplakia
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2003079993A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
US20050287203A1 (en) 2002-05-08 2005-12-29 Nijs De H Formulation comprising testosteron undecanoate and castor oil
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
PT1542670E (pt) 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US20040097419A1 (en) 2002-11-19 2004-05-20 Holger Petersen Organic compounds
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
EP1592416B1 (en) 2003-02-07 2009-01-07 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
GB0307082D0 (en) 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
DE10328905B4 (de) 2003-06-26 2015-07-09 Hochland Natec Gmbh Form- und Kühlvorrichtung
WO2005002592A2 (en) 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
WO2005021013A1 (ja) 2003-09-01 2005-03-10 Earthus, Inc. β−ヒドロキシ短〜中鎖脂肪酸重合体
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN1863505A (zh) 2003-10-10 2006-11-15 卫材株式会社 新型液体制剂组合物
WO2005041901A2 (en) 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Therapeutics using somatostatin agonists
EP1682091B1 (en) 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
CA2558393A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20050256097A1 (en) 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
CN1960746A (zh) 2004-05-25 2007-05-09 阿尔扎公司 稳定性提高的含生物分子配方
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060014712A1 (en) 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
US20060002989A1 (en) 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
JP5513713B2 (ja) 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
AU2005286640A1 (en) 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
MX2007010394A (es) 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
EP1871348A4 (en) 2005-03-01 2012-08-01 Sun Pharma Advanced Res Co Ltd PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
NZ561400A (en) 2005-03-11 2010-02-26 Endo Pharmaceuticals Solutions Controlled release formulations of octreotide
US7759312B2 (en) 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
WO2006127214A1 (en) 2005-05-23 2006-11-30 Mayo Foundation For Medical Education And Research Treating liver diseases
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US20070021325A1 (en) 2005-07-21 2007-01-25 Mediplex Corporation Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
ES2581212T3 (es) 2005-11-07 2016-09-02 Murty Pharmaceuticals, Inc. Administración mejorada de tetahidrocannabinol
EP2275103B1 (en) 2005-11-21 2014-04-23 Novartis AG mTOR inhibitors in the treatment of endocrine tumors
RU2464972C2 (ru) 2005-12-22 2012-10-27 Новартис Аг Композиции с замедленным высвобождением, включающие октреотид и два или более сополимера полилактида и гликолида
TW200738269A (en) 2006-02-09 2007-10-16 Univ Maryland Oral delivery of therapeutic agents using tight junction agonists
US20070190139A1 (en) 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
US20070224142A1 (en) 2006-03-22 2007-09-27 Swaile David F Hydrogenated castor oil based compositions as a replacement for petrolatum
MX2008012844A (es) 2006-04-06 2009-01-19 Activbiotics Pharma Llc Composiciones farmaceuticas y usos de ellas.
WO2007117706A2 (en) 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8071136B2 (en) 2006-04-21 2011-12-06 Bioactives, Inc. Water-soluble pharmaceutical compositions of hops resins
MX2008015666A (es) 2006-06-08 2009-01-12 Novartis Ag Combinacion de analogos de somatostatina con un agonista de dopamina o un antagonista del receptor de hormona de crecimiento.
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
JP4588791B2 (ja) 2007-02-16 2010-12-01 あすか製薬株式会社 微粒子油性懸濁液を含む医薬組成物
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
GB2454672A (en) 2007-11-13 2009-05-20 Mologic Ltd Chromogenic protease substrates
WO2009102443A2 (en) 2008-02-15 2009-08-20 The Government Of The Usa, As Represented By The Secretary Of The Dept. Of Health & Human Services; Octanoic acid formulations and methods of treatment using the same
CN102046192B (zh) 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
ES3058497T3 (en) 2008-09-17 2026-03-11 Amryt Endo Inc Pharmaceutical compositions comprising polypeptides and related methods of delivery
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
EP2477566B1 (en) 2009-09-14 2017-03-22 Synthes GmbH Variable angle compression plate
JP2011113487A (ja) 2009-11-30 2011-06-09 Hochiki Corp 警報器の設置方法、警報器および支持部材
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
BR112014030777A2 (pt) 2012-06-21 2017-06-27 Angiogene Pharm Ltd método e composição para aliviar sintomas de tumor
WO2014049515A1 (en) 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
US20150283147A1 (en) 2012-10-19 2015-10-08 Synta Pharmaceuticals Corp. Treating polycystic kidney disease with hsp90 inhibitory compounds
WO2016048984A1 (en) 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
PL3253401T3 (pl) * 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
IL311974A (en) 2016-01-21 2024-06-01 Amryt Endo Inc Somatostatin receptor ligands such as octreotide for oral administration to treat the disease
IL313083A (en) 2016-10-21 2024-07-01 Amryt Endo Inc Terlipressin compositions and their methods of use
US20220202911A1 (en) 2020-12-28 2022-06-30 Amryt Endo, Inc. Oral octreotide therapy in combination with digoxin or lisinopril
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
EP4482491A4 (en) 2022-02-25 2026-02-25 Amryt Endo Inc ORAL OCTREOTIDE FOR THE TREATMENT OF A DISEASE

Also Published As

Publication number Publication date
US20190298792A1 (en) 2019-10-03
US20240082343A1 (en) 2024-03-14
HUE071943T2 (hu) 2025-10-28
ZA202301198B (en) 2024-05-30
US10238709B2 (en) 2019-03-26
AU2016215350B2 (en) 2021-11-25
IL277235A (en) 2020-10-29
WO2016126830A1 (en) 2016-08-11
HK1247818A1 (en) 2018-10-05
ES3029566T3 (en) 2025-06-24
US10695397B2 (en) 2020-06-30
US20220233630A1 (en) 2022-07-28
US20200390847A1 (en) 2020-12-17
PT3253401T (pt) 2025-06-04
ZA201808086B (en) 2023-12-20
US20220378867A1 (en) 2022-12-01
US12251418B2 (en) 2025-03-18
DK3253401T3 (da) 2025-05-19
SMT202500243T1 (it) 2025-07-22
NZ734894A (en) 2024-11-29
FI3253401T3 (fi) 2025-07-09
AU2022201269B2 (en) 2024-03-14
PL3253401T3 (pl) 2025-08-04
EP3253401B1 (en) 2025-04-02
US20240245748A1 (en) 2024-07-25
SI3253401T1 (sl) 2025-07-31
AU2022201269A1 (en) 2022-03-17
AU2024203939B2 (en) 2026-03-19
AU2024203939A1 (en) 2024-07-04
CA2975599A1 (en) 2016-08-11
US20210052691A1 (en) 2021-02-25
AU2016215350A1 (en) 2017-09-14
US11338011B2 (en) 2022-05-24
MA41462B1 (fr) 2025-04-30
EP3253401A1 (en) 2017-12-13
US20240245749A1 (en) 2024-07-25
IL253706A0 (en) 2017-09-28
US11857595B2 (en) 2024-01-02
ZA201705877B (en) 2019-03-27
EP3253401A4 (en) 2018-11-21
US20160220628A1 (en) 2016-08-04
MD3253401T2 (ro) 2025-07-31
RS66942B1 (sr) 2025-07-31
HRP20250645T1 (hr) 2025-07-18
EP4527456A3 (en) 2025-05-21
US12246054B2 (en) 2025-03-11
US11510963B1 (en) 2022-11-29
MA41462A (fr) 2021-05-12
EP4527456A2 (en) 2025-03-26
US11052126B2 (en) 2021-07-06

Similar Documents

Publication Publication Date Title
ZA201803101B (en) Oral treatment device
IL259458A (en) Oral care device
IL248856A0 (en) New treatment
SMT202500243T1 (it) Trattamento dell’acromegalia con octreotide orale
GB201502137D0 (en) Treatment
SI3685682T1 (sl) Peroralni sestavek za re-hidratacijo
GB201522243D0 (en) Treatment
GB2532060B (en) Artificial teeth
ES3066409T3 (en) Octreotide injection
GB201519450D0 (en) Novel treatment
GB201508841D0 (en) Treatment
GB201503008D0 (en) Treatment
SI3303486T1 (sl) Sestavek za površinsko obdelavo
SG11201706885RA (en) Novel treatment method
GB201411027D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201518349D0 (en) Treatment
GB201515739D0 (en) Treatment
GB201404013D0 (en) Hypertension treatment
GB201514008D0 (en) Treatment
GB201517957D0 (en) Artificial diamonds
GB201516389D0 (en) Artificial diamonds
SG10201507842WA (en) Grinding method
GB201505579D0 (en) Interdental brush
GB201502307D0 (en) Interdental brush